Introduction {#j_jccm-2020-0009_s_002}
============

Gut dysfunction (GDF) is a common problem in critically ill patients. It is the leading cause of multiple organ dysfunction syndrome/failure (MODS/MOF) and a significant cause of mortality and morbidity in critically ill patients \[[@j_jccm-2020-0009_ref_001]\]. In addition to this, the treatment of acute and critical illness can exacerbate GDF. Commonly used ICU interventions such as intravenous fluid resuscitation, early aggressive enteral feeding and vasopressor therapy are key factors leading to a secondary gut injury. In critical illness, intravenous fluid is the mainstay of early management for hemo-dynamic instability. It is vital to resuscitate a patient before commencing vasopressor therapy, particularly to delay the onset of an ischemic insult commonly occurring in hemodynamically unstable patients \[[@j_jccm-2020-0009_ref_002]\]. On the flip side, over-resuscitation can lead to bowel oedema leading to an ileus, while under-resuscitation with persistent splanchnic and peripheral vasoconstriction can trigger intestinal mucosal ischemia \[[@j_jccm-2020-0009_ref_003]\]. Although, enteral nutrition is the preferred approach to meet nutritional and modest fluid requirements in these patients, the delivery of early but aggressive enteral nutrition (EN) in hemodynamically unstable patients can precipitate the development of severe GDF, potentially leading to non-occlusive mesenteric ischemia which increases the chance of sepsis, multi-organ failure and mortality \[[@j_jccm-2020-0009_ref_004]\]. Intravenous fluid and enteral nutrition are two sides of the same coin and play a crucial role in determining the outcome of GDF if used wisely. However, very few studies have evaluated the role of these two modalities, thus making it difficult to understand their relationship with relevance to the severity of GDF. The aim was to review the evidence of the impact of intravenous fluid resuscitation and enteral nutrition individually on determinants of gut function and the implications in clinical practice.

Methods {#j_jccm-2020-0009_s_003}
=======

Search Criteria and Study Identification {#j_jccm-2020-0009_s_003_s_001}
----------------------------------------

Electronic databases (MEDLINE and EMBASE) were searched using keywords on 'gastrointestinal dysfunction in adult intensive care unit (ICU) /surgical patients on enteral feeding and intravenous fluids. The databases screened for all publications from the earliest available until 16^th^ October 2018 (Appendix A).

Randomised controlled trials were searched by applying the keywords. Any additional studies on the impact of 'intravenous fluid' and 'enteral feeding' were included in the screening for the systematic review and meta-analysis. The search identification, screening and selection were conducted by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart (Fig1) \[[@j_jccm-2020-0009_ref_005]\]. The study selection criteria were as follows.

The inclusion criteria were:

*Study design*: all randomised controlled trials (intravenous fluids and enteral feeding on GDF);

*Study population*: Adult surgical and critically ill patients

*Disease state*: critical illness and postoperative conditions

*Intervention*: **enteral feeding**: route of feeding (enteral vs parenteral); timing of feeding (early vs delayed); feeding vs nil-by-mouth and **intravenous fluids**: restricted vs liberal regime, goal-directed vs standard/conventional, low-infusions vs high-infusion or controlled vs rapid fluid therapy; intravenous fluids type: crystalloid fluid (normal saline or plasmalyte or ringer's lactate) or colloid fluid (hydroxyethyl starch, albumin, gelofusion).

*Study outcome*: the occurrence of gastrointestinal dysfunction

The studies were excluded if they were:

-   non-ICU or non-surgical patients

-   paediatric population

-   animal studies

-   published in non-English languages

-   conducted on healthy volunteers

-   non-randomized trials (intravenous fluid therapy and enteral feeding)

-   not relevant to either of the interventions planned to study pattern of feeding (bolus vs continuous), comparative feed compositions (standard vs immune-enriched), related routes of feeding (nasogastric vs nasojejunal or jejunal) and studies addressing medications (e.g. prokinetic therapy).

*Data Extraction*: Data were extracted and independently recorded by two authors using predesigned data collection forms on Microsoft Excel.

Study characteristics included baseline demographic data such as author, publication year, study setting (ICU or surgical ward), admission diagnosis, study population, the total number of patients, fluid or enteral feeding interventions applied to experimental and control groups. The effect of fluid therapy and enteral feeding on GDF was analysed by separating the severity of GDF outcomes: 1) *mild to moderate* and 2) *moderate to severe*. All studies were stratified into the Clavien-Dindo classification \[[@j_jccm-2020-0009_ref_006]\] depending on the variability of clinical aetiology and interventions applied. Any additional studies derived from other sources and reference lists of included articles were screened and included if relevant. Data were independently reviewed and cross-checked by two authors (V.A. and A.B.). Any inconsistencies or disagreements were discussed between the two authors (V.A. and A.B.), and differences of opinion were further clarified by the senior author (J.A.W.).

Methodological quality {#j_jccm-2020-0009_s_003_s_002}
----------------------

The methodological quality of included randomised controlled trials was assessed according to the Cochrane recommendations (The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) \[[@j_jccm-2020-0009_ref_007]\]. These included systematic differences between groups (selection bias and performance bias), blinding of study participants and assessors, sequence allocation and concealment of allocated groups, the validity of findings and data withdrawal, incomplete outcome data (attrition and detection bias), and differences between data reporting or unreported data. The risk of bias assessment was presented according to the Cochrane collaboration recommendations. The overall quality of the study was graded as *'poor', 'fair*' and *'good*' based on the classification in the Cochrane's quality assessment tool.

Statistical Analysis {#j_jccm-2020-0009_s_003_s_003}
--------------------

All data were presented as the number of episodes of GDF in patients. Data analysis and interpretation were performed using Revman 5.3 (Revman, Version 5.3 for Windows; Copenhagen, Denmark: the Nordic Cochrane Centre, The Cochrane Collaboration, 2008) \[[@j_jccm-2020-0009_ref_007]\]. The nature of the analysis was not suitable for a pooled data analysis. Within each class of interventions (intravenous fluid and enteral feeding), a meta-analysis of GDF events was performed. Quantitative data meta-analysis was performed with at least two studies reporting on GDF as the primary or secondary outcome. Studies that did not have GDF as a primary or secondary outcome were excluded from the meta-analyses (Fig 1).

Heterogeneity was assessed by using I^2^ and classified as \< 25% - low ; 25 -- 50% - moderate and \> 75% as high heterogeneity (heterogeneity and subgroup analysis in Cochrane consumers and communication group reviews) \[[@j_jccm-2020-0009_ref_008]\]. Regardless of the presence or absence of heterogeneity, a random-effects model was used to provide the most conservative estimate. Pooled effects for classes of interventions were calculated as weighted mean difference (MD) with 95% confidence interval (CI). P-value \< 0.05 was considered statistically significant for all analyses. Ethical approval was not necessary for a review of published trials.

Results {#j_jccm-2020-0009_s_004}
=======

Study Selection and Characteristics {#j_jccm-2020-0009_s_004_s_001}
-----------------------------------

A total of 103 studies including intravenous fluids (n = 46) and enteral feeding (n = 57) were eligible for inclusion in the systematic review, of which 43 (n = 22 intravenous fluid; n = 21 enteral feeding) studies were included in the final meta-analyses.

In studies on *intravenous fluid therapy* \[[@j_jccm-2020-0009_ref_009], [@j_jccm-2020-0009_ref_010], [@j_jccm-2020-0009_ref_011], [@j_jccm-2020-0009_ref_012], [@j_jccm-2020-0009_ref_013], [@j_jccm-2020-0009_ref_014], [@j_jccm-2020-0009_ref_015], [@j_jccm-2020-0009_ref_016], [@j_jccm-2020-0009_ref_017], [@j_jccm-2020-0009_ref_018], [@j_jccm-2020-0009_ref_019], [@j_jccm-2020-0009_ref_020], [@j_jccm-2020-0009_ref_021], [@j_jccm-2020-0009_ref_022], [@j_jccm-2020-0009_ref_023], [@j_jccm-2020-0009_ref_024], [@j_jccm-2020-0009_ref_025], [@j_jccm-2020-0009_ref_026], [@j_jccm-2020-0009_ref_027], [@j_jccm-2020-0009_ref_028], [@j_jccm-2020-0009_ref_029], [@j_jccm-2020-0009_ref_030], [@j_jccm-2020-0009_ref_031], [@j_jccm-2020-0009_ref_032], [@j_jccm-2020-0009_ref_033], [@j_jccm-2020-0009_ref_034], [@j_jccm-2020-0009_ref_035], [@j_jccm-2020-0009_ref_036], [@j_jccm-2020-0009_ref_037], [@j_jccm-2020-0009_ref_038], [@j_jccm-2020-0009_ref_039], [@j_jccm-2020-0009_ref_040], [@j_jccm-2020-0009_ref_041], [@j_jccm-2020-0009_ref_042], [@j_jccm-2020-0009_ref_043], [@j_jccm-2020-0009_ref_044], [@j_jccm-2020-0009_ref_045], [@j_jccm-2020-0009_ref_046], [@j_jccm-2020-0009_ref_047], [@j_jccm-2020-0009_ref_048], [@j_jccm-2020-0009_ref_049], [@j_jccm-2020-0009_ref_050], [@j_jccm-2020-0009_ref_051], [@j_jccm-2020-0009_ref_052], [@j_jccm-2020-0009_ref_053], [@j_jccm-2020-0009_ref_054]\], 46 randomised controlled trials' including 20,780 patients were systematically reviewed, of which 22 studies (n = 2696) were included in the final meta-analysis. Ten studies included mechanical ventilated critically ill patients, and the remaining 36 studies included post-operative patients. The intervention group received either restricted, goal-directed, low-infusion fluids or a controlled-expansion fluid regime given as crystalloid fluid (normal saline or plasmalyte) or colloid fluid (hydroxyethyl starch). The control group included standard, liberal, conventional, high-infusion fluids or rapid-expansion fluid regimes given as crystalloid fluids (ringers lactate, plasmalyte and saline). Five studies compared more than two groups of fluid regimes. Fifteen studies included critically ill, trauma and surgical patients with a grading of IV as per the Clavien-Dindo classification (Appendix B). The remaining studies included postoperative and acutely ill patients with Clavien-Dindo grading of II and III ([Tables 1](#j_jccm-2020-0009_tab_001){ref-type="table"}-[3](#j_jccm-2020-0009_tab_003){ref-type="table"}).

###### 

Study Characteristics of \'good\' quality studies on the impact of intravenous fluid therapy on gut dysfunction included in the systematic review

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                          Year   Study Population                Study\    Study\   Study\     Admission diagnosis                            Experimental   Intravenous\   Control   Intravenous\      Dindo-Clavien\
                                                                                         Setting   type     patients                                                                 fluid                    fluid             Classification\*
  ----------------------------------------------- ------ ------------------------------- --------- -------- ---------- ---------------------------------------------- -------------- -------------- --------- ----------------- ------------------
  Brandstrup^[@j_jccm-2020-0009_ref_009]^         2003   elective colorectal resection   surgery   RCT      141        postsurgical                                   69             restricted     72        standard          

  Holte^[@j_jccm-2020-0009_ref_010]^              2007   elective surgery                surgery   RCT      32         elective colorectal surgery                    16             restricted     16        liberal           

  Holte^[@j_jccm-2020-0009_ref_011]^              2007   post-surgery                    surgery   RCT      48         knee arthroplasty                              24             restricted     24        liberal           

  Gonsalez-Fajardo^[@j_jccm-2020-0009_ref_012]^   2009   post-surgery                    surgery   RCT      40         vascular surgery transperitoneal aorto-iliac   20             restricted     20        standard          

  Yates^[@j_jccm-2020-0009_ref_013]^              2013   elective surgery                surgery   RCT      206        elective colorectal surgery                    104            starch         98        crystalloid       

  Ghodraty^[@j_jccm-2020-0009_ref_014]^           2017   post-surgery                    surgery   RCT      91         abdominal surgery                              46             HES            45        ringers lactate   

  Gómez-Izquierdo^[@j_jccm-2020-0009_ref_015]^    2017   post-surgery                    surgery   RCT      128        colorectal surgery                             4              GDFT           64        control           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HES- hydroxyethyl starch; GDFT-goal-directed fluid therapy; RCT-randomised controlled trial. \* Appendix C

###### 

Study Characteristics of \'fair \' quality studies on the impact of intravenous fluid therapy on gut dysfunction.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                    Year   Study Population                                            Study\     Study\   Study\     Admission\       Experimental                                              Intravenous\   Control   Intravenous\   Dindo-Clavien\
                                                                                                               Setting    type     patients   diagnosis                                                                  fluid                    fluid          Classification\*
  ----------------------------------------- ------ ----------------------------------------------------------- ---------- -------- ---------- ---------------- --------------------------------------------------------- -------------- --------- -------------- ------------------
  Gan^[@j_jccm-2020-0009_ref_016]^          2002   major elective general, urologic, or gynaecologic surgery   surgery    RCT      100        postsurgical     50                                                        GDFT           50        Standard       

  Moretti^1\ 7^                             2003   Major elective cardiac surgery                              surgery    RCT      90         postsurgical     30 - HetaStarch normal saline; 30 Heta Starch Balanced\                                           
                                                                                                                                                               salt; 30 Lactated Ringers                                                                         

  Nisanevich^[@j_jccm-2020-0009_ref_018]^   2005   elective intraabdominal surgery                             surgery    RCT      157        postsurgical     77                                                        Restrictive    75        Liberal        

  Kabon^[@j_jccm-2020-0009_ref_019]^        2005   open colonic resection                                      surgery    RCT      253        ICU surgical     124                                                       Small volume   129       Large Volume   

  Lopes^[@j_jccm-2020-0009_ref_020]^        2007   High-risk surgery                                           surgery    RCT      33         ICU surgical     17                                                        GDFT           16        Control        

  Vermuelen^[@j_jccm-2020-0009_ref_021]^    2009   elective major abdominal surgical procedures                surgical   RCT      62         surgical         30                                                        Restricted     32        Standard       

  Mayer^[@j_jccm-2020-0009_ref_022]^        2010   major abdominal surgery                                     surgery    RCT      60         ICU surgical     30                                                        GDFT           30        Standard       

  SAFE ^[@j_jccm-2020-0009_ref_023]^        2011   ICU                                                         ICU        RCT      1218       ICU              603                                                       Colloid        615       Crystalloid    

  Guidet^[@j_jccm-2020-0009_ref_024]^       2012   severe sepsis                                               ICU        RCT      196        ICU              100                                                       Colloid        96        Crystalloid    

  Perner^[@j_jccm-2020-0009_ref_025]^       2012   severe sepsis                                               ICU        RCT      798        ICU              398                                                       Colloid        400       Crystalloid    

  Reddy^[@j_jccm-2020-0009_ref_026]^        2016   critically ill                                              ICU        RCT      69         critically ill   35                                                        plasmalyte     34        saline         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GDFT-goal-directed fluid therapy; ICU -intensive care unit; S-ICU -surgical ICU; RCT-randomised controlled trial; \* Appendix C

###### 

Study Characteristics of \'poor \' quality studies on the impact of intravenous fluid therapy on gut dysfunction.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                   Year   Study Population                 Study\     Study\   Study\     Admission diagnosis                         Experimental                                                       Intravenous\                 Control   Intravenous fluid          Dindo-Clavien\           
                                                                                   Setting    type     patients                                                                                                                  fluid                                                             Classification\*         
  ---------------------------------------- ------ -------------------------------- ---------- -------- ---------- ------------------------------------------- ------------------------------------------------------------------ ---------------------------- --------- -------------------------- ------------------ -- -- --
  Prein^[@j_jccm-2020-0009_ref_027]^       1990   post-surgery                     surgery    RCT      18         modified Whipple\'s                         6- ringers\' lactate; 6-- starch; 6-albumin                        I                            II        III                        IV                       

  Salim^[@j_jccm-2020-0009_ref_028]^       1991   elective surgery                 surgery    RCT      130        Hartmann\'s procedure +/- cholecystectomy   71                                                                 early oral                   59        conventional intravenous                            

  Yogendran^[@j_jccm-2020-0009_ref_029]^   1995   elective surgery                 surgical   RCT      200        surgical                                    100                                                                Low-infusion                 100       High infusion                                       

  Wilkes^[@j_jccm-2020-0009_ref_030]^      2001   elective, open surgical          surgical   RCT      47         surgical                                    23                                                                 Balanced                     24        Saline                                              

  Lobo ^[@j_jccm-2020-0009_ref_031]^       2002   post-surgery                     surgery    RCT      20         colorectal surgery                          10                                                                 restricted                   10        liberal                                             

  Conway^[@j_jccm-2020-0009_ref_032]^      2002   major bowel surgery              surgical   RCT      57         surgical                                    28                                                                 GDFT                         39        Standard                                            

  Venn^[@j_jccm-2020-0009_ref_033]^        2002   hip fracture surgery             surgical   RCT      90         surgical                                    29CON- VF ; CVP guided FT- 3 1 ; Doppler-guided FT- 30                                                                                                        

  SAFE^[@j_jccm-2020-0009_ref_034]^        2004   ICU                              ICU        RCT      6997       ICU                                         3497                                                               Colloid                      3500      Crystalloid                                         

  Parker^[@j_jccm-2020-0009_ref_035]^      2004   hip fracture surgery             surgical   RCT      396        surgical                                    198                                                                Colloid                      198       Crystalloid                                         

  Noblett^[@j_jccm-2020-0009_ref_036]^     2005   elective colorectal resection    surgical   RCT      108        surgical                                    54                                                                 GDFT                         54        Standard                                            

  Wakeling^[@j_jccm-2020-0009_ref_037]^    2005   large bowel surgery              surgical   RCT      128        surgical                                    64                                                                 GDFT                         64        Standard                                            

  Mackay^[@j_jccm-2020-0009_ref_038]^      2006   elective colorectal surgery      surgical   RCT      80         surgical                                    41                                                                 Restricted                   39        Standard                                            

  En-quiang^[@j_jccm-2020-0009_ref_038]^   2009   critically ill                   S-ICU      RCT      76         severe acute pancreatitis                   30                                                                 controlled fluid expansion   30        rapid fluid expansion                               

  Senagore^[@j_jccm-2020-0009_ref_040]^    2009   laparoscopic\                    surgical   RCT      64         surgical                                    21 GDFT/LR; 21 GDFT/HS;2 22 standard                                                                                                                          
                                                  colectomy                                                                                                                                                                                                                                                                 

  Futier^[@j_jccm-2020-0009_ref_041]^      2010   major abdominal surgery          surgery    RCT      70         postsurgical                                36                                                                 Restricted-GDFT              34        Conservative GDFT                                   

  Benes^[@j_jccm-2020-0009_ref_042]^       2010   elective intraabdominal\         surgery    RCT      120        ICU surgical                                60                                                                 GDFT                         60        Standard                                            
                                                  surgery                                                                                                                                                                                                                                                                   

  Pillai^[@j_jccm-2020-0009_ref_043]^      2011   post-surgery                     surgery    RCT      66         radical cystectomy                          34                                                                 intervention                 32        control                                             

  Du^[@j_jccm-2020-0009_ref_044]^          2011   critically ill                   ICU        RCT      41         severe acute pancreatitis                   20                                                                 starch                       21        ringers\' lactate                                   

  James^[@j_jccm-2020-0009_ref_045]^       2011   Blunt and penetrating\           surgical   RCT      109        surgical                                    Penetrating trauma- HES 36 ; SAL 31 Blunt trauma- HES20 ; SAL 22                                                                                              
                                                  trauma                                                                                                                                                                                                                                                                    

  Challand^[@j_jccm-2020-0009_ref_046]^    2012   major elective colorectal\       surgical   RCT      179        surgical                                    90                                                                 GDFT                         89        Standard                                            
                                                  surgery                                                                                                                                                                                                                                                                   

  Myberg^[@j_jccm-2020-0009_ref_047]^      2012   ICU                              ICU        RCT      7000       ICU                                         3500                                                               Colloid                      3500      Crystalloid                                         

  Srinivasa^[@j_jccm-2020-0009_ref_048]^   2012   elective colectomy               surgical   RCT      85         surgical                                    37                                                                 GDFT Restricted              37        Restricted                                          

  Zheng^[@j_jccm-2020-0009_ref_049]^       2013   post-surgery                     surgery    RCT      60         gastrointestinal surgery                    30                                                                 GDFT                         30        control                                             

  Scheeren^[@j_jccm-2020-0009_ref_050]^    2013   High-risk surgery                ICU        RCT      52         ICU                                         26                                                                 GDFT                         26        Control                                             

  Pestana^[@j_jccm-2020-0009_ref_051]^     2014   post-surgery                     S-ICU      RCT      142        abdominal surgery                           70                                                                 GDFT                         72        control                                             

  Pearse^[@j_jccm-2020-0009_ref_052]^      2014   Major Gastrointestinal\          surgery    RCT      734        surgical                                    368                                                                GDFT                         366       Standard                                            
                                                  Surgery                                                                                                                                                                                                                                                                   

  Peng^[@j_jccm-2020-0009_ref_053]^        2014   elective surgery                 surgery    RCT      80         orthopaedic surgery                         40                                                                 GDFT                         40        standard                                            

  Reisinger^[@j_jccm-2020-0009_ref_054]^   2017   elective colorectal resection\   surgery    RCT      58         postsurgical                                27                                                                 GDFT                         31        Standard                                            
                                                  for malignancy                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: : HES- hydroxyethyl starch ; HS- hetastach; SAL- saline; LR- lactate ringers; GDFT-goal-directed fluid therapy; ICU - intensive care unit ; S-ICU -surgical ICU; CON-IVF- conventional intravenous fluid therapy; CVP- central venous pressure; FT-fluid therapy RCT-randomised controlled trial; \* Appendix C

In studies on *enteral feeding* \[[@j_jccm-2020-0009_ref_055], [@j_jccm-2020-0009_ref_056], [@j_jccm-2020-0009_ref_057], [@j_jccm-2020-0009_ref_058], [@j_jccm-2020-0009_ref_059], [@j_jccm-2020-0009_ref_060], [@j_jccm-2020-0009_ref_061], [@j_jccm-2020-0009_ref_062], [@j_jccm-2020-0009_ref_063], [@j_jccm-2020-0009_ref_064], [@j_jccm-2020-0009_ref_065], [@j_jccm-2020-0009_ref_066], [@j_jccm-2020-0009_ref_067], [@j_jccm-2020-0009_ref_068], [@j_jccm-2020-0009_ref_069], [@j_jccm-2020-0009_ref_070], [@j_jccm-2020-0009_ref_071], [@j_jccm-2020-0009_ref_072], [@j_jccm-2020-0009_ref_073], [@j_jccm-2020-0009_ref_074], [@j_jccm-2020-0009_ref_075], [@j_jccm-2020-0009_ref_076], [@j_jccm-2020-0009_ref_077], [@j_jccm-2020-0009_ref_078], [@j_jccm-2020-0009_ref_079], [@j_jccm-2020-0009_ref_080], [@j_jccm-2020-0009_ref_081], [@j_jccm-2020-0009_ref_082], [@j_jccm-2020-0009_ref_083], [@j_jccm-2020-0009_ref_084], [@j_jccm-2020-0009_ref_085], [@j_jccm-2020-0009_ref_086], [@j_jccm-2020-0009_ref_087], [@j_jccm-2020-0009_ref_088], [@j_jccm-2020-0009_ref_089], [@j_jccm-2020-0009_ref_090], [@j_jccm-2020-0009_ref_091], [@j_jccm-2020-0009_ref_092], [@j_jccm-2020-0009_ref_093], [@j_jccm-2020-0009_ref_094], [@j_jccm-2020-0009_ref_095], [@j_jccm-2020-0009_ref_096], [@j_jccm-2020-0009_ref_097], [@j_jccm-2020-0009_ref_098], [@j_jccm-2020-0009_ref_099], [@j_jccm-2020-0009_ref_100], [@j_jccm-2020-0009_ref_101], [@j_jccm-2020-0009_ref_102], [@j_jccm-2020-0009_ref_103], [@j_jccm-2020-0009_ref_104], [@j_jccm-2020-0009_ref_105], [@j_jccm-2020-0009_ref_106], [@j_jccm-2020-0009_ref_107], [@j_jccm-2020-0009_ref_108], [@j_jccm-2020-0009_ref_109], [@j_jccm-2020-0009_ref_110], [@j_jccm-2020-0009_ref_111]\], 57 randomised controlled trials', included nearly 50% of the cohort as critically ill patients while the remaining were admitted as acute or elective surgical patients with variable admission diagnoses. The experimental group included enteral feeding delivered based on the route of feeding (enteral vs parenteral; nasogastric vs nasojejunal or jejunostomy), the timing of feeding (early vs delayed), the pattern of feeding (bolus vs continuous), or enteral feeding vs nil-by-mouth (NBM) with/without intravenous fluid. Twenty-four studies included critically ill, multiple trauma or sepsis patients with a Clavien-Dindo grading of IV. The remaining studies included post-operative and acutely ill patients with Clavien-Dindo grading of II and III ([Tables 4](#j_jccm-2020-0009_tab_004){ref-type="table"}-[6)](#j_jccm-2020-0009_tab_006){ref-type="table"}.

###### 

Study Characteristics of studies on the impact of enteral feeding on gut dysfunction included in the systematic review

  Author                                         Year   Study Population         Study Setting     Study type   Study patients   Admission diagnosis               Experimental                               Control              Dindo-Clavien Classification\#   Quality Grading\*             
  ---------------------------------------------- ------ ------------------------ ----------------- ------------ ---------------- --------------------------------- ------------------------------------------ -------------------- -------------------------------- ------------------- -- ------ ------
  Hoover^[@j_jccm-2020-0009_ref_055]^            1980   surgical                 surgical          RCT          48               surgical                          26 EF                                      22IVF                                                                               Poor
  Adams^[@j_jccm-2020-0009_ref_056]^             1986   ICU surgical             ICU               RCT          46               multiple trauma                   23 (EN)                                    23(PN)                                                                              Poor
  Moore^[@j_jccm-2020-0009_ref_057]^             1986   major abdo trauma        surgical          RCT          59               surgical                          29 (EN)                                    30 (PN)                                                                             Poor
  Bower^[@j_jccm-2020-0009_ref_058]^             1986   surgical                 surgery           RCT          20               GI/pancreato-biliary surgery      10 (EN-JeJ)                                10 (PN)                                                                             Poor
  Hamoui^[@j_jccm-2020-0009_ref_059]^            1989   surgical                 surgical          RCT          19               major GI surgery                  11EN                                       8PN                                                                                 Poor
  Von Meyenfeldt^[@j_jccm-2020-0009_ref_060]^    1992   surgical                 surgery           RCT          101              GI/colon cancer                   50 (EN)                                    51(PN)                                                                              Poor
  Montecalvo^[@j_jccm-2020-0009_ref_061]^        1992   surgical                 surgical          RCT          38               surgical                          19 NG                                      19 NJ                                                                               Poor
  Dunham^[@j_jccm-2020-0009_ref_062]^            1994   critically ill           ICU               RCT          37               trauma                            12 (EN)+ 15 (PN) + 10(EN+PN)                                                                                            Poor   
  Borzotta^[@j_jccm-2020-0009_ref_063]^          1994   trauma                   surgical trauma   RCT          48               trauma                            27 (EN)                                    21(PN)                                                                              Poor
  Daly^[@j_jccm-2020-0009_ref_064]^              1995   surgical                 surgical          RCT          60               surgical                          18ENSD; 12SD-IP; 19 ENSD-IP-OP; 11 EN-IP                                                                                Poor   
  Carr^[@j_jccm-2020-0009_ref_065]^              1996   post-surgical            surgery           RCT          28               intestinal resection              14(EEN)                                    14(CEN)                                                                             Poor
  Beier-Holgersen^[@j_jccm-2020-0009_ref_066]^   1996   post-surgical            surgery           RCT          60               major abdominal surgery           30(EEN)                                    30 (placebo)                                                                        Poor
  Baigrie^[@j_jccm-2020-0009_ref_067]^           1996   post-surgical            surgery           RCT          97               oesophagectomy/gastrectomy        50 (EN)                                    47(PN)                                                                              Poor
  VanBerge^[@j_jccm-2020-0009_ref_068]^          1997   post-surgical            surgery           RCT          57               pancreatoduodenectomy             30 (CON)                                   27(CYC)                                                                             Poor
  Kalfarentzos^[@j_jccm-2020-0009_ref_069]^      1997   critically ill           ICU               RCT          38               Severe acute pancreatitis         18(EN)                                     20 (PN)                                                                             
  Heslin^[@j_jccm-2020-0009_ref_070]^            1997   surgical                 surgery           RCT          195              upper GI malignancy               97 (EN)                                    98(IVF)                                                                             Poor
  Reynolds^[@j_jccm-2020-0009_ref_071]^          1997   major upper GI surgery   surgical          RCT          67               surgical                          33 (EN)                                    34(PN)                                                                              Poor
  Stewart^[@j_jccm-2020-0009_ref_072]^           1998   elective surgical        surgery           RCT          80               colorectal resections             40 (EOF)                                   40 (COF)                                                                            Poor
  Windsor^[@j_jccm-2020-0009_ref_073]^           1998   surgical                 surgical          RCT          34               acute pancreatitis                16 EN                                      18PN                                                                                Poor
  Singh^[@j_jccm-2020-0009_ref_074]^             1998   surgical                 surgical          RCT          43               surgical                          22JEJ                                      21IVF                                                                               Poor
  Braga^[@j_jccm-2020-0009_ref_075]^             1998   surgical                 surgical          RCT          166              surgical                          55 STD-EN; 55 -STD-EN enriched; 56 TPN                                                                                  Poor   
  Taylor^[@j_jccm-2020-0009_ref_076]^            1999   critically ill           ICU               RCT          82               head injury                       41TRO                                      41 EN                                                                               Fair
  Pupelis^[@j_jccm-2020-0009_ref_077]^           2000   critically ill           S-ICU             RCT          60               severe pancreatitis/peritonitis   30 (JEN)                                   30 (Control)                                                                        Poor
  Minard^[@j_jccm-2020-0009_ref_078]^            2000   critically ill           ICU               RCT          27               head injury/trauma                12(EEN)                                    15(DEN)                                                                             Poor
  Powell^[@j_jccm-2020-0009_ref_079]^            2000   critically ill           ICU               RCT          27               severe acute pancreatitis         13 (EN)                                    14(NBM)                                                                             Poor
  Kearns^[@j_jccm-2020-0009_ref_080]^            2000   critically ill           ICU               RCT          44               critically ill                    23 G                                       21 SI                                                                               Poor
  Bozzetti^[@j_jccm-2020-0009_ref_081]^          2001   elective surgery         surgery           RCT          317              GIcancer                          159(EN)                                    158(PN)                                                                             Poor
  Braga^[@j_jccm-2020-0009_ref_082]^             2001   surgical                 surgery           RCT          257              GIcancer                          126(EEN)                                   131(PN)                                                                             Poor
  Montejo^[@j_jccm-2020-0009_ref_083]^           2002   critically ill           ICU               RCT          101              critically ill                    50 (JEN)                                   51(GEN)                                                                             Poor
  Davies^[@j_jccm-2020-0009_ref_084]^            2002   critically ill           ICU               RCT          73               critically ill                    34 (NJ)                                    39 (NG)                                                                             Poor
  Bertolini^[@j_jccm-2020-0009_ref_085]^         2003   critically ill           ICU               RCT          39               Sepsis                            18(EN)                                     17 (PN)                                                                             Poor
  Kompan^[@j_jccm-2020-0009_ref_086]^            2004   critically ill           ICU               RCT          52               multiple trauma                   27(EEN)                                    21(DEN)                                                                             Poor
  Malhotra^[@j_jccm-2020-0009_ref_087]^          2004   post-surgical            surgery           RCT          164              perforated gut and peritonitis    83 (EN)                                    81(NBM)                                                                             Poor
  Kumar^[@j_jccm-2020-0009_ref_088]^             2006   Surgical                 surgical          RCT          31               surgical                          15 NG                                      16 NJ                                                                               Poor
  Nguyen^[@j_jccm-2020-0009_ref_089]^            2007   critically ill           ICU               RCT          31               critically ill                    23 (NJ)                                    28 (NJ)                                                                             Poor
  Han-Guerts^[@j_jccm-2020-0009_ref_090]^        2007   post-surgical            surgery           RCT          150              oesophagectomy                    71 (ND)                                    79 (JEJ)                                                                            Poor
  Descahy^[@j_jccm-2020-0009_ref_091]^           2008   critically ill           ICU               RCT          100              ICU                               50EEN                                      50CEN                                                                               Poor
  Tien^[@j_jccm-2020-0009_ref_092]^              2009   critically ill           ICU               RCT          200              ICU                               98TRO                                      102 EN                                                                              Poor
  Barlow^[@j_jccm-2020-0009_ref_093]^            2011   Surgical                 surgery           RCT          121              upper GI malignancy               64 (EN)                                    57(NBM+IVF)                                                                         Poor
  Altintas^[@j_jccm-2020-0009_ref_094]^          2011   critically ill           ICU               RCT          71               ICU                               30 (EN)                                    41 (PN)                                                                             Poor
  Rice^[@j_jccm-2020-0009_ref_095]^              2011   Surgical                 surgical          RCT          247              surgical                          EN 123                                     124 IVF                                                                             Poor
  Davies^[@j_jccm-2020-0009_ref_096]^            2013   critically ill           ICU               RCT          181              ICU                               91 NJ                                      89 NG                                                                               Poor
  Zhu^[@j_jccm-2020-0009_ref_097]^               2013   post-surgical            surgery           RCT          68               pancreaticoduodenectomy           34(JT)                                     34(NJT)                                                                             Poor
  Sun^[@j_jccm-2020-0009_ref_098]^               2013   critically ill           S-ICU             RCT          60               severe acute pancreatitis         30(EEN)                                    30(DEN)                                                                             Poor
  Kadamani^[@j_jccm-2020-0009_ref_009]^9         2014   critically ill           ICU               RCT\#        15               critically ill                    15 (CON)                                   15 (BOL)                                                                            Poor
  Boelens^[@j_jccm-2020-0009_ref_100]^           2014   elective surgical        surgery           RCT          123              rectal surgery                    61(EEN)                                    62(EPN)                                                                             Poor
  Harvey^[@j_jccm-2020-0009_ref_101]^            2014   critically ill           ICU               RCT          2388             critically ill                    1197(EN)                                   1191(PN)                                                                            Poor
  Ma^[@j_jccm-2020-0009_ref_102]^                2015   acute surgical           surgery           RCT          35               acute pancreatitis                17 (NTF)                                   18(NPO)                                                                             Poor
  Bing Li^[@j_jccm-2020-0009_ref_103]^           2015   post-surgical            surgery           RCT          400              gastrectomy                       200(EEN)                                   200 (PN)                                                                            Poor
  Taylor^[@j_jccm-2020-0009_ref_104]^            2016   critically ill           ICU               RCT          50               critically ill                    25 (NJ)                                    25(NG + ProK)                                                                       Poor
  Ozen^[@j_jccm-2020-0009_ref_105]^              2016   critically ill           ICU               RCT          51               critically ill                    26(no-GRV\'s)                              25(GRV\'s)                                                                          Poor
  Van Barneveld^[@j_jccm-2020-0009_ref_106]^     2016   elective surgical        surgery           RCT          123              rectal ca malignancy              61 (EEN)                                   62(EPN)                                                                             Good
  Malik^[@j_jccm-2020-0009_ref_107]^             2016   critically ill           ICU               RCT          60               critically ill                    30 (EF)                                    30 (placebo)                                                                        Poor
  Fan^[@j_jccm-2020-0009_ref_108]^               2016   critically ill           ICU               RCT          80               Severe TBI                        40 (EN)                                    40 (PN)                                                                             Poor
  Stimac^[@j_jccm-2020-0009_ref_109]^            2016   acute pancreatitis       pancreatitis      RCT          214              acute pancreatitis                107 EN                                     107 IVF                                                                             Poor
  Hongyin^[@j_jccm-2020-0009_ref_110]^           2017   acute surgical           surgery           RCT          161              acute pancreatitis                83 (APD)/61 EN)                            78(non-APD)/68(EN)                                                                  Poor
  Reigner^[@j_jccm-2020-0009_ref_111]^           2018   critically ill           ICU               RCT          2410             shock                             1202(EN)                                   1208(PN)                                                                            Fair

*Abbreviations : EEN--- early enteral feeding; CEN--- conventional enteral feeding; EN--- enteral nutrition; PN parenteral nutrition; CON--- continuous enteral feeding; CYC --- cyclic enteral feeding; EOF --- early oral feeding ; COF --- conventional oral feeding ;JEN---jejunal enteral nutrition; DEN--- delayed enteral nutrition ; NBM --- nil by mouth; GEN --- gastric enteral nutrition ; NJ --- nasojejunal; NG nasogastric; ND --- nasoduodenal; JEJ- jejunostomy ; JT ---jejeunostomy tube ; NJT --- nasojejunal tube; BOL ---bolus ; EPN --- early parenteral nutrition; NTF --- nasogastric tube feeding; NPO ---nil per oral; ProK---prokinetics; GRV--- gastric residual volumes; APD --- abdominalparacentesis drainage ;ICU --- intensive care unit ; S-ICU --- surgical ICU; RCT --- randomised controlled trial, \# - pseudo-RCT; GI--- gastrointestinal; TBI --- traumatic brain injury; IVF --- intravenous fluids; TRO- trophic feeding; ENSD --- enteral nutrition with supplemented diet; IP inpatient; OP --- outpatient; STD --- standard; \# D-C classification Appendix C;* \* *Thresholds for Converting the Cochrane Risk of Bias Tool.*

###### 

Impact of intravenous fluid therapy on variables of gut dysfunction

  Symptoms of GDF ^§^      Intervention^al^   Control   Odds Ratio \[95% CI\]^\*^   P Trend    I^2^ (%)^\#^
  ------------------------ ------------------ --------- --------------------------- ---------- --------------
  Nausea                   88/ 274            90/278    0.98 (0.67, 1.44)           0.92       0
  Vomiting                 62/462             94/447    0.51 (0.28, 0.94)           **0.03**   45
  Ileus                    66/832             80/828    0.83 (0.52, 1.32)           0.42       23
  GI bleed                 15/592             10/587    1.48 (0.66, 3.35)           0.34       0
  Anastomotic leak         44/833             43/867    1.03 (0.54, 1.96)           0.93       31
  Perforation              7/238              6/234     1.05 (0.36, 3.09)           0.92       0
  Intestinal obstruction   5/451              11/445    0.53 (0.20, 1.45)           0.22       0

a: restricted, goal-directed, low-infusions or a controlled-expansion fluid therapy given as crystalloid fluid (normal saline or plasmalyte) or colloid fluid (hydroxyethyl starch)

b: standard, liberal, conventional, high-infusions or rapid-expansion fluid regimes given as crystalloid fluids (ringers lactate, plasmalyte and saline).

\*CI - Confidence interval used; Significant P values (\<0.05) are shown in bold; \#I2 - heterogeneity between studies expressed as percentages; § GDF - gut dysfunction

###### 

Impact of enteral feeding on variables of gut dysfunction as classified by feeding categories

  Symptoms of GDF^§^                             Intervention Enteral   Control Parenteral   Odds \[95% Ratio CI\]\*   P Trend      I^2^ \[%\]^\#^
  ---------------------------------------------- ---------------------- -------------------- ------------------------- ------------ ----------------
  **A. Route of feeding**                                                                                                           
  Vomiting                                       605/2388               350/2598             2.02 (1.74, 2.35)         **\<0.01**   0
  Diarrhoea                                      190/1508               421/1515             1.75 (0.39, 7.86)         0.46         92
  Abdominal distension                           123/1386               90/1390              1.51 (0.93, 2.45)         0.10         28
  Ileus                                          52/347                 65/347               0.97 (0.34, 2.76)         0.96         58
  Anastomotic leak                               28/540                 54/545               0.54 (0.31, 0.95)         **0.03**     14
  Intestinal ischaemia                           33/2493                16/2495              1.87 (0.72, 4.87)         0.20         42
  Peritonitis                                    5/265                  18/268               0.31 (0.11, 0.87)         **0.03**     0
                                                                                                                                    
  **B. Timing of feeding**                       Early                  Delayed                                                     
  Vomiting                                       3/56                   19/54                0.11 (0.03, 0.41)         **\<0.01**   0
  Diarrhoea                                      27/39                  23/40                2.45 (0.26, 22.75)        0.43         69
  Abdominal Distension                           12/66                  21/69                0.51 (0.22, 1.91)         0.12         0
                                                                                                                                    
  **C. Enteral feeding vs Nil-by-mouth (NBM)**   Enteral                NBM                                                         
  Vomiting                                       21/220                 22/219               0.72 (0.18, 2.90)         0.65         0
  Abdominal Distension                           66/242                 48/240               1.40 (0.75, 2.64)         0.29         33
  GI bleed                                       2/133                  2/133                0.99 (0.17, 5.86)         0.99         0
  Anastomotic leak                               12/244                 24/236               0.46 (0.22, 0.95)         **0.04**     0

\*CI - Confidence interval used; Significant P values (\<0.05) are shown in bold; \#I2 - heterogeneity between studies expressed as percentages; § GDF - gut dysfunction

Quality assessment {#j_jccm-2020-0009_s_004_s_002}
------------------

The quality of studies was graded based on the Cochrane Quality assessment tool for randomised controlled trials for intravenous fluid ([Tables 1](#j_jccm-2020-0009_tab_001){ref-type="table"}-[3](#j_jccm-2020-0009_tab_003){ref-type="table"}) and enteral feeding ([Table 4](#j_jccm-2020-0009_tab_004){ref-type="table"}) studies (Appendix C and D). All studies met the criteria for randomisation and allocation concealment, but a wide variability existed between studies for other domains (blinding of participants and personnel, blinding of outcome assessment and assessor, incomplete outcome data and selective reporting). In the intravenous fluid group, quality assessment for 7 studies \[[@j_jccm-2020-0009_ref_009], [@j_jccm-2020-0009_ref_010], [@j_jccm-2020-0009_ref_011], [@j_jccm-2020-0009_ref_012], [@j_jccm-2020-0009_ref_013], [@j_jccm-2020-0009_ref_014], [@j_jccm-2020-0009_ref_015]\] (15%) scored *'good*' ([Table 1](#j_jccm-2020-0009_tab_001){ref-type="table"}), 11 studies \[[@j_jccm-2020-0009_ref_016], [@j_jccm-2020-0009_ref_017], [@j_jccm-2020-0009_ref_018], [@j_jccm-2020-0009_ref_019], [@j_jccm-2020-0009_ref_020], [@j_jccm-2020-0009_ref_021], [@j_jccm-2020-0009_ref_022], [@j_jccm-2020-0009_ref_023], [@j_jccm-2020-0009_ref_024], [@j_jccm-2020-0009_ref_025], [@j_jccm-2020-0009_ref_026]\] (22%) scored *'fair*' ([Table 2](#j_jccm-2020-0009_tab_002){ref-type="table"}), and more than half (63%) of the studies \[[@j_jccm-2020-0009_ref_027], [@j_jccm-2020-0009_ref_028], [@j_jccm-2020-0009_ref_029], [@j_jccm-2020-0009_ref_030], [@j_jccm-2020-0009_ref_031], [@j_jccm-2020-0009_ref_032], [@j_jccm-2020-0009_ref_033], [@j_jccm-2020-0009_ref_034], [@j_jccm-2020-0009_ref_035], [@j_jccm-2020-0009_ref_036], [@j_jccm-2020-0009_ref_037], [@j_jccm-2020-0009_ref_038], [@j_jccm-2020-0009_ref_039], [@j_jccm-2020-0009_ref_040], [@j_jccm-2020-0009_ref_041], [@j_jccm-2020-0009_ref_042], [@j_jccm-2020-0009_ref_043], [@j_jccm-2020-0009_ref_044], [@j_jccm-2020-0009_ref_045], [@j_jccm-2020-0009_ref_046], [@j_jccm-2020-0009_ref_047], [@j_jccm-2020-0009_ref_048], [@j_jccm-2020-0009_ref_049], [@j_jccm-2020-0009_ref_050], [@j_jccm-2020-0009_ref_051], [@j_jccm-2020-0009_ref_052], [@j_jccm-2020-0009_ref_053], [@j_jccm-2020-0009_ref_054]\] w*ere 'poor*' ([Table 3](#j_jccm-2020-0009_tab_003){ref-type="table"}). In the enteral feeding group, the majority (95%) of the studies \[[@j_jccm-2020-0009_ref_055], [@j_jccm-2020-0009_ref_056], [@j_jccm-2020-0009_ref_057], [@j_jccm-2020-0009_ref_058], [@j_jccm-2020-0009_ref_059], [@j_jccm-2020-0009_ref_060], [@j_jccm-2020-0009_ref_061], [@j_jccm-2020-0009_ref_062], [@j_jccm-2020-0009_ref_063], [@j_jccm-2020-0009_ref_064], [@j_jccm-2020-0009_ref_065], [@j_jccm-2020-0009_ref_066], [@j_jccm-2020-0009_ref_067], [@j_jccm-2020-0009_ref_068], [@j_jccm-2020-0009_ref_069], [@j_jccm-2020-0009_ref_070], [@j_jccm-2020-0009_ref_071], [@j_jccm-2020-0009_ref_072], [@j_jccm-2020-0009_ref_073], [@j_jccm-2020-0009_ref_074], [@j_jccm-2020-0009_ref_075],[@j_jccm-2020-0009_ref_077], [@j_jccm-2020-0009_ref_078], [@j_jccm-2020-0009_ref_079], [@j_jccm-2020-0009_ref_080], [@j_jccm-2020-0009_ref_081], [@j_jccm-2020-0009_ref_082], [@j_jccm-2020-0009_ref_083], [@j_jccm-2020-0009_ref_084], [@j_jccm-2020-0009_ref_085], [@j_jccm-2020-0009_ref_086], [@j_jccm-2020-0009_ref_087], [@j_jccm-2020-0009_ref_088], [@j_jccm-2020-0009_ref_089], [@j_jccm-2020-0009_ref_090], [@j_jccm-2020-0009_ref_091], [@j_jccm-2020-0009_ref_092], [@j_jccm-2020-0009_ref_093], [@j_jccm-2020-0009_ref_094], [@j_jccm-2020-0009_ref_095], [@j_jccm-2020-0009_ref_096], [@j_jccm-2020-0009_ref_097], [@j_jccm-2020-0009_ref_098], [@j_jccm-2020-0009_ref_099], [@j_jccm-2020-0009_ref_100], [@j_jccm-2020-0009_ref_101], [@j_jccm-2020-0009_ref_102], [@j_jccm-2020-0009_ref_103], [@j_jccm-2020-0009_ref_104], [@j_jccm-2020-0009_ref_105],[@j_jccm-2020-0009_ref_107], [@j_jccm-2020-0009_ref_108], [@j_jccm-2020-0009_ref_109], [@j_jccm-2020-0009_ref_110]\] scored 'poor'; two studies scored *'fair*' \[[@j_jccm-2020-0009_ref_076], [@j_jccm-2020-0009_ref_111]\] and 1 study \[[@j_jccm-2020-0009_ref_106]\] was of *'good*' quality ([Table 4](#j_jccm-2020-0009_tab_004){ref-type="table"}).

Quantitative data analysis {#j_jccm-2020-0009_s_004_s_003}
--------------------------

### Impact of intravenous fluid therapy on GDF {#j_jccm-2020-0009_s_004_s_003_s_001}

Twenty-two randomised controlled trials \[[@j_jccm-2020-0009_ref_009],[@j_jccm-2020-0009_ref_010],[@j_jccm-2020-0009_ref_013], [@j_jccm-2020-0009_ref_014], [@j_jccm-2020-0009_ref_015], [@j_jccm-2020-0009_ref_016],[@j_jccm-2020-0009_ref_018], [@j_jccm-2020-0009_ref_019], [@j_jccm-2020-0009_ref_020], [@j_jccm-2020-0009_ref_021], [@j_jccm-2020-0009_ref_022],[@j_jccm-2020-0009_ref_026],[@j_jccm-2020-0009_ref_028],[@j_jccm-2020-0009_ref_031],[@j_jccm-2020-0009_ref_041], [@j_jccm-2020-0009_ref_042], [@j_jccm-2020-0009_ref_043],[@j_jccm-2020-0009_ref_049],[@j_jccm-2020-0009_ref_051], [@j_jccm-2020-0009_ref_052], [@j_jccm-2020-0009_ref_053], [@j_jccm-2020-0009_ref_054]\] evaluated *mild to moderate* (nausea, vomiting and ileus) *and moderate to severe* (GI bleed, anastomotic leak, perforation and intestinal obstruction) GDF in 7368 patients, of which, 3682 (50%) were randomised to the intervention group (goal-directed/ restricted/ balanced intravenous fluids) and the remaining to the control group (liberal/ standard intravenous fluid). In the intervention group, no significant difference was observed for nausea, ileus, GI bleed, anastomotic leak, perforation or intestinal obstruction, in the intervention group in comparison to the control group. However, restricted/goal-directed fluid therapy in the form of colloids (starch/albumin) or a balanced fluid solution (plasmalyte /ringers lactate) was likely to reduce 'mild' GDF such as vomiting (*p* = *0.03*) in critically ill and major surgical patients compared to a standard/liberal intravenous fluid regime ([Table 5](#j_jccm-2020-0009_tab_005){ref-type="table"}). Heterogeneity between studies ranged from 0 - 45 %.

### Impact of enteral feeding on GDF {#j_jccm-2020-0009_s_004_s_003_s_002}

Twenty-one randomised controlled trials' \[[@j_jccm-2020-0009_ref_060],[@j_jccm-2020-0009_ref_063],[@j_jccm-2020-0009_ref_067], [@j_jccm-2020-0009_ref_070],[@j_jccm-2020-0009_ref_071], [@j_jccm-2020-0009_ref_072], [@j_jccm-2020-0009_ref_073],[@j_jccm-2020-0009_ref_075],[@j_jccm-2020-0009_ref_078],[@j_jccm-2020-0009_ref_081],[@j_jccm-2020-0009_ref_085], [@j_jccm-2020-0009_ref_086], [@j_jccm-2020-0009_ref_087],[@j_jccm-2020-0009_ref_091],[@j_jccm-2020-0009_ref_093],[@j_jccm-2020-0009_ref_094],[@j_jccm-2020-0009_ref_100],[@j_jccm-2020-0009_ref_101],[@j_jccm-2020-0009_ref_106], [@j_jccm-2020-0009_ref_108],[@j_jccm-2020-0009_ref_111]\] enrolled 18,543 patients of which, 50% (n = 9260) patients were randomised to the enteral nutrition groups. The remaining half (n = 9283) were randomised to the parenteral nutrition group, delayed enteral feeding or nil-by-mouth group. *Mild to moderate* GDF (vomiting, diarrhoea, abdominal distention and ileus) and *moderate to severe* (GI bleed, anastomotic leak, intestinal ischaemia, peritonitis) are presented in sub-groups (route of feeding -- enteral vs. parenteral; the timing of feeding -- early vs. delayed and feeding vs no feeding -- enteral vs. nil-by-mouth) demonstrated in [Table 6](#j_jccm-2020-0009_tab_006){ref-type="table"}.

#### (i). Route of feeding (enteral vs parenteral) {#j_jccm-2020-0009_s_004_s_003_s_002_s_001}

In the EN group, a significant increase in vomiting episodes was observed compared to in parenteral nutrition group (*p* \< *0.01*). The EN group showed a trend in fewer events for anastomotic leaks (*p* = *0.03*) and peritonitis (*p* = *0.03*) compared to the parenteral nutrition group. Other variables of GDF, including diarrhoea, abdominal distension and intestinal ischemia, presented with no significant differences between the two groups ([Table 6](#j_jccm-2020-0009_tab_002){ref-type="table"}). Heterogeneity between studies ranged from 0 -- 92 %.

#### (ii). Timing of feeding (early vs delayed) {#j_jccm-2020-0009_s_004_s_003_s_002_s_002}

Four randomised controlled trials' enrolled 324 patients, of which 50% of patients were allocated to the early enteral nutrition group and the other half to the delayed/conventional enteral nutrition group. A significant decrease in the vomiting episodes was observed in the early enteral nutrition group compared to delayed/conventional enteral nutrition group (*p* \< *0.01*). No differences were observed between groups for diarrhoea and abdominal distension. Heterogeneity between studies ranged from 0 -- 69 %.

#### (iii). Enteral feeding vs nil-by-mouth (NBM) {#j_jccm-2020-0009_s_004_s_003_s_002_s_003}

Six randomised controlled trials' enrolled 1667 patients, of which 50% was randomised to the intervention group. There was a tendency of reduced anastomotic leaks in patients receiving enteral feeding (*p* = *0.04*) compared to patients on a nil-by-mouth regimen. However, no differences were observed for events on vomiting, abdominal distension and GI bleed. ([Table 6](#j_jccm-2020-0009_tab_002){ref-type="table"}). Heterogeneity between studies ranged from 0 -- 33 %.

Discussion {#j_jccm-2020-0009_s_005}
==========

The results of the meta-analysis demonstrate that restricted/goal-directed fluid therapy regardless of the type of fluid reduces mild GDF (vomiting) but not other complications associated with GDF. Enteral feeding, on the other hand, significantly increased vomiting episodes compared to parenteral nutrition but 'early' enteral nutrition significantly reduced the incidence of vomiting compared to delayed feeding. Enteral feeding was likely to reduce severe gut complications such as anastomotic leak and peritonitis compared with parenteral nutrition or an NBM status. Other mild to moderate variables of GDF (i.e. nausea, abdominal distension, ileus or diarrhoea) and moderate to severe complications (i.e. GI bleed, perforation, intestinal obstruction or intestinal ischaemia) were not associated with significant changes in outcomes. The results suggest that although the beneficial effects of restricted/goal-directed intravenous fluids and enteral feeding are essential to reduce some form of GDF, the impact is not prevalent for other variables of GDF (e.g. ileus and intestinal ischemia) associated with poor clinical outcomes. This may reflect the paucity of high-quality literature on the interaction between intravenous fluid (resuscitation) and enteral feeding as a combined therapy on the impact of GDF. The role of these two modalities in combination should be regarded as an important aspect in identifying the impact on the severity of GDF in acute surgical and critically ill patients.

*Intravenous fluid therapy* is frequently the first line of treatment in acute surgical and critically ill patients but hypervolemia and hypovolemia, both, are deemed detrimental. A revival of interest emerged almost two decades ago when hypovolemia in the form of restrictive fluid therapy was associated with improved post-operative clinical outcomes \[[@j_jccm-2020-0009_ref_009],[@j_jccm-2020-0009_ref_016],[@j_jccm-2020-0009_ref_018],[@j_jccm-2020-0009_ref_031]\]. These studies suggested that a preferred approach of 'zero' or 'neutral' fluid balance not only improves outcomes related to gut motility but also may prevent adverse long-term outcomes. The current study demonstrated that mild GDF, i.e. vomiting, was significantly lower in patients on a restrictive/ targeted intravenous fluid regime. Studies have also reported similar results when colloids have been administered postoperatively \[[@j_jccm-2020-0009_ref_014],[@j_jccm-2020-0009_ref_017]\]. The benefit of this outcome may be explained by cumulative administration of smaller volumes (of colloids) compared to crystalloids. Hypervolemia from excessive or liberal fluid administration, particularly crystalloids is associated with poor outcomes in postoperative \[[@j_jccm-2020-0009_ref_009],[@j_jccm-2020-0009_ref_018]\] and in critically ill patients \[[@j_jccm-2020-0009_ref_025],[@j_jccm-2020-0009_ref_047]\]. It can precipitate intestinal oedema leading to an ileus, delayed gastric emptying, feeding intolerance and hence sub-optimal nutrition delivery. Another school of thought indicates that complex surgical patients with high-risk surgeries possibly require judicious amounts of fluids to avoid complications associated with circulatory failure and gut mucosal ischemia \[[@j_jccm-2020-0009_ref_041],[@j_jccm-2020-0009_ref_054],[@j_jccm-2020-0009_ref_116],[@j_jccm-2020-0009_ref_119]\]. This may be particularly relevant when liberal intravenous fluids are necessary to resuscitate patients after massive haemorrhagic losses for haemodynamic stability. In recent decades, goal-directed fluids have been advocated to prevent tissue hypovolemia \[[@j_jccm-2020-0009_ref_020]\] but maintain euvolemia by using targeted fluid approach raising the possibility of improved clinical outcomes in high-risk patients \[[@j_jccm-2020-0009_ref_022], [@j_jccm-2020-0009_ref_042], [@j_jccm-2020-0009_ref_084],[@j_jccm-2020-0009_ref_121]\]. Hence, it is expected that a modest amount of fluids might be necessary to prevent anastomotic hypoperfusion, gut mucosal ischemia and reduce postoperative complications. Although the benefit of goal-directed fluid therapy is projected at improving organ perfusion without the onset of tissue oedema \[[@j_jccm-2020-0009_ref_054],[@j_jccm-2020-0009_ref_117],[@j_jccm-2020-0009_ref_122]\]; a paucity of studies exists warranting more research in this area \[[@j_jccm-2020-0009_ref_015], [@j_jccm-2020-0009_ref_041], [@j_jccm-2020-0009_ref_052], [@j_jccm-2020-0009_ref_118]\].

*Enteral Nutrition* forms an integral part of overall fluid administration in addition to intravenous fluids. Enteral nutrition and intravenous fluids combined play a crucial role in GDF outcomes, but due to a paucity of studies, this area has not received due attention. Enteral nutrition is invariably the first choice of nutrition compared to parenteral nutrition over decades \[[@j_jccm-2020-0009_ref_112]\]. The current study demonstrated that mild GDF, i.e. vomiting significantly increased in patients receiving enteral nutrition but reduced significantly when enteral feeding was commenced earlier. This is possible because 'early' enteral nutrition has multiple advantages over parenteral nutrition \[[@j_jccm-2020-0009_ref_075],[@j_jccm-2020-0009_ref_082],[@j_jccm-2020-0009_ref_114],[@j_jccm-2020-0009_ref_121]\], and these benefits are evident in high-risk surgical and critically ill patients \[[@j_jccm-2020-0009_ref_070],[@j_jccm-2020-0009_ref_124]\]. The initiation of enteral feeding is known to stimulate gut motility which reduces the incidence of GDF symptoms such as nausea and vomiting postoperatively. However, a significant difference for ileus between groups was not observed, although the number of events were lower in the enterally fed group. In cases of gut failure, when enteral feeding is contraindicated, parenteral nutrition becomes the sole choice of feeding and may be commenced within 24 hrs of ICU admission or post-surgery \[[@j_jccm-2020-0009_ref_120]\]. Administering parenteral nutrition appears to be a logical clinical decision, especially if enteral feeding raises the suspicion of non-occlusive mesenteric ischemia in the critically ill, with haemodynamic compromise. Our review showed no differences for intestinal \'ischaemia\' between groups, although the events were half in the control group compared to the intervention (enteral nutrition) arm. Considering that the current review included a heterogeneous mix of patients, it is evident that in a sub-set of patients, i.e. post-cardiac surgery, severe acute pancreatitis or septic shock, administration of early enteral nutrition may potentially pose more risk than benefit by increasing the risk of bowel ischemia.

Nevertheless, the use of trophic enteral feeding has been suggested in haemodynamically unstable patients to maintain gut integrity \[[@j_jccm-2020-0009_ref_004]\]. Authors have argued that enteral nutrition comes with its risks such as aspiration, pneumonia, intestinal obstruction, necrosis and pneumonitis intestinalis. However, the present study demonstrated no such differences for any of these complications. For gastrointestinal complications, a significant reduction in anastomotic leaks in the enteral nutrition group suggesting its benefits irrespective of the feeding route was observed. It is common practice in some areas, particularly intensive care, to commence patients on parenteral nutrition with anastomotic leaks before a trial of enteral nutrition. However, it should be acknowledged that a correct assessment for an enteral nutrition challenge can be countered in patients on parenteral nutrition with significant complications (e.g. anastomotic leaks), hence lowering the threshold of initiating enteral nutrition. Barlow et al. \[[@j_jccm-2020-0009_ref_093]\] found a lower incidence (2 vs 7) of anastomotic leaks in the early enteral nutrition group. They attributed a three-day shorter length of stay and reduced postoperative complications from installing early enteral nutrition. A similar effect was confirmed by a Cochrane review \[[@j_jccm-2020-0009_ref_115]\] in which enteral nutrition reduced the risk of anastomotic leaks from 27% in the standard group to 13% in early enteral group. These results affirmed with the present findings. It is hypothesised that enteral nutrition may improve perfusion at the anastomosis site, which promotes mucosal wound healing and prevents further leaks.

In comparison, Lewis et al. (2009) did not support this finding and observed mortality of 50% in the intervention group (enteral group) with anastomotic leaks \[[@j_jccm-2020-0009_ref_114]\]. However, it is likely that a smaller sample size may result in a false positive rate for mortality, thus exaggerating the magnitude of the negative result. The benefit of enteral feeding in complications such as perforation and peritonitis has been confirmed by several reports, which resonated with our findings. Early enteral feeding seems to maintain gut integrity by improving mucosal circulation and oxygen delivery that may reduce the risk of peritonitis \[[@j_jccm-2020-0009_ref_074], [@j_jccm-2020-0009_ref_087],[@j_jccm-2020-0009_ref_113]\].

The present study is not without limitations:

1.  The severity score in majority of the studies including surgical patients was low (ranging between I to III) hence the overall effect may be confounded by the clinical severity of the cohort. The majority of studies were conducted in stable postoperative patients and results may not be generalisable to a high-risk group, e.g. septic shock.

2.  Critically ill patients are a heterogeneous group, and the effect on gut function can differ with specific sub-population. Such high-risk heterogenous patients need to be assessed in robust, well-designed, and randomised controlled trials. A possible stumbling block may be the ethical dilemma of implementing clinical trials using regimented interventions in these patients is often challenging for institutions and ethics committees.

3.  Individualised unit protocols were variable with prescription of fluid and enteral feeding regimes possibly confounding the overall impact on GDF outcomes.

4.  Most studies included small numbers of patients and were single-centred studies.

5.  Postoperative morbidity manifested as GDF may be associated with the type of surgical procedure or manipulation of the bowel during surgery which may be associated with inducing a surgical stress response. However, this is expected to be low in our study, considering that the majority of the cohort included stable postoperative patients.

6.  The majority of our studies found no differences between long-term endpoints (mortality and length of stay) but the occurrence of GDF was excluded from primary endpoints.

7.  Most importantly, it was difficult to define or classify gut dysfunction because, until now, there is no valid, objective or a reliable scoring system to assess gut function in intensive care patients \[125\]. This suggests the need to develop a novel scoring tool to address this concern in future trials. Due to fewer studies on the effect of intravenous fluids and enteral nutrition on GDF, our meta-analyses may have been underpowered to see significant outcomes on GDF. Overall, studies on intravenous fluid remain mostly inconclusive, and potentially the impact of intravenous fluids may project variable outcomes when applied to a homogenous cohort instead of heterogeneous patient groups.

Further, inconclusive results from large-scale fluid and enteral feeding trials raise the suspicion that GDF may be the missing link, which perhaps may be associated with long-term outcomes. This dimension is often ignored when evaluating endpoints. To observe a difference in the key outcome, we first need to understand the combined effects of intravenous fluids and enteral nutrition in influencing clinical outcomes, including GDF. It is expected that as a result of the potential interaction between these two modalities, patients receiving liberal fluid resuscitation and early aggressive feeding are more likely to be at risk of severe GDF. More work is required to understand the implications of intravenous fluids and enteral nutrition on GDF and how this may impact overall patient outcomes. Future studies should evaluate this potential interaction and assess the combined impact of these two modalities on GDF in surgical and critically ill patients.

Conclusion {#j_jccm-2020-0009_s_006}
==========

A restricted/goal-directed fluid regime and early enteral feeding compared to parenteral or a nil-by-mouth regime may reduce the risk on mild GDF in some, but not all complications of severe GDF. Because of a preventive strategy, we need to first understand the interaction between both (intravenous fluids and enteral feeding) and their impact on the gut so its implications can be translated into clinical practice eventually. Hence, it can be hypothesised that conservative fluid resuscitation and aggressive enteral feeding may potentially be the fundamental cause of developing severe life-threatening GDF (i.e. intestinal ischemia) and complications that can delay recovery and affect clinical outcomes in acute surgical and critically ill patients. Future research should evaluate and focus on an extended conceptual framework on the cross-interaction of conservative and aggressive modes across these two interventions and its impact on various levels of severity of GDF.
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###### 

Search Strategy

  \# Searches Results
  ------------------------------------------------------------------------------------------------------------------------------------
  1 Gastrointestinal Diseases/
  2 ((gastrointestinal or intestin\* or digestive) adj3 (dysfunction\* or failure or disorder\* or injur\* or disease\*)).mp.
  3 ((abdominal or gut or bowel or intestin\*) adj3 (perforat\* or infarct\* or obstruct\* or failure or ischemi\*)).mp.
  4 gastroparesis.mp. or Gastroparesis/
  5 gastrointestinal motilit\*.mp. or exp Gastrointestinal Motility/
  6 (dysmotilit\* or intestinal motilit\*).mp. 5645
  7 Intra-Abdominal Hypertension/
  8 (abdominal compartment syndrome\* or intra abdominal hypertension or intraabdominal hypertension).mp.
  9 feed\* intolerance.mp.
  10 ileus.mp. or Ileus/
  11 Intestinal Obstruction/ or Intestinal Pseudo-Obstruction/ or pseudo obstruction.mp. or ogilvie's syndrome.mp.
  12 (mesenteric or peritonitis).mp. 91360
  13 or/1-12 282880
  14 enteral nutrition/ or parenteral nutrition/
  15 Parenteral Nutrition, Total/
  16 ((enteral or parenteral) adj3 (feed\* or nutrition)).mp.
  17 Fluid Therapy/ or intravenous fluid\*.mp.
  18 (fluid\* adj3 therap\*).mp.
  19 (resuscitation adj3 fluid\*).mp.
  20 vasoactive.mp.
  21 Vasoconstrictor Agents/ or vasoconstrictor\*.mp. or vasopressor\*.mp.
  22 inotrope\*.mp.
  23 or/14-22
  24 intensive care/ or critical illness/
  25 Intensive Care Units/
  26 General Surgery/
  27 Postoperative Complications/ or Postoperative Care/
  28 (intensive care or ICU or critical care or critical\* ill\*).mp.
  29 (surgery or surgical or postoperative).mp.
  30 or/24-29
  31 randomized controlled trial.pt.
  32 controlled clinical trial.pt.
  33 randomized.ab.
  34 placebo.ab. 35 drug therapy.fs.
  36 randomly.ab.
  37 trial.ab. 38 groups.ab.
  39 or/31-38
  40 adult/ or aged/ or "aged, 80 and over"/ or frail elderly/ or middle aged/ or (adult\* or middle aged or older or old or aged or
  elderly or geriatric\* or frail).mp.
  41 13 and 23 and 30 and 39 and 40
  42 exp animals/ not humans.sh
  43 41 not 42

###### 

Dindo-Clavien Classification

  Grade       Grade Definition
  ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Grade I     Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics, electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside
  Grade II    Requiring pharmacological treatment with drugs other than such allowed for grade I complications, Blood transfusions and total parenteral nutrition are also included
  Grade III   Requiring surgical, endoscopic or radiological intervention Grade IIIa Intervention not under general anaesthesia Grade IIIb Intervention under general anaesthesia
  Grade IV    Life-threatening complication (including CNS complications)\* requiring IC/ICU management Grade IVa Single organ dysfunction (including dialysis) Grade IVb Multiorgan dysfunction)

Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications: A New Proposal with Evaluation in a Cohort of 6336 Patients and Results of a Survey. Annals of Surgery. 2004; 240 (2): 205-213.

###### 

Quality assessment for studies on the effect of intravenous fluid therapy on gut dysfunction (Cochrane quality grading for randomised controlled trials)^7^

  ---------------------------
  ![](jccm-06-005-e005.jpg)
  ---------------------------

\*Thresholds for Converting the Cochrane Risk of Bias Tool: Good quality: All criteria met (i.e. low for each domain); Fair quality: One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was unlikely to have biased the outcome, and there is no known important limitation that could invalidate the results Poor quality: One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was likely to have biased the outcome, and there are significant limitations that could invalidate the results OR Two or more criteria listed as high or unclear risk of bias

###### 

Quality assessment for studies on the effect of enteral feeding on gut dysfunction (Cochrane quality grading for randomised controlled trials)^7^

  ---------------------------
  ![](jccm-06-005-e006.jpg)
  ---------------------------

\*Thresholds for Converting the Cochrane Risk of Bias Tool: Good quality: All criteria met (i.e. low for each domain); Fair quality: One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was unlikely to have biased the outcome, and there is no known significant limitation that could invalidate the results; Poor quality: One criterion not met (i.e. high risk of bias; for one domain) or two criteria unclear, and the assessment that this was likely to have biased the outcome, and there are significant limitations that could invalidate the results OR Two or more criteria listed as high or unclear risk of bias
